Guardant Health CFO awarded 26,582 RSUs

Bell Michael Brian reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Bell Michael Brian reported acquisition or exercise transactions in this Form 4 filing.

Guardant Health, Inc. Chief Financial Officer Michael Brian Bell received a grant of 26,582 restricted stock units on March 11, 2026 as equity compensation. The award vests over three years: 33% on April 1, 2027 and the remaining 67% in equal quarterly installments over the following two years, settling in common stock as units vest.

Insider Trade Summary

Grant/Award: 26,582 shares

Grant/Award 1 txn

Insider Bell Michael Brian

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	26,582	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 26,582 contracts (Direct)

Footnotes (2)

1. F1. This represents a restricted stock unit award granted on March 11, 2026 that vests over a three-year period. 33% of the shares subject to such award will vest on April 1, 2027 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
2. F2. Not applicable for Restricted Stock Units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Guardant Health (GH) report for its CFO?

Guardant Health reported that CFO Michael Brian Bell received 26,582 restricted stock units as an equity grant. These RSUs represent a compensation award, not an open-market share purchase or sale, and will convert into common stock only as they vest over time.

How many Guardant Health RSUs were granted to the CFO in this Form 4?

The Form 4 shows a grant of 26,582 restricted stock units to Guardant Health CFO Michael Brian Bell. All 26,582 units are reported as held following the transaction, reflecting his new RSU position from this single award as of the grant date.

What is the vesting schedule for the Guardant Health CFO’s 26,582 RSUs?

The 26,582 RSUs vest over three years. According to the filing, 33% of the units vest on April 1, 2027, while the remaining 67% vests in equal quarterly installments over the subsequent two-year period, subject to continued service conditions.

Are the Guardant Health CFO’s RSUs an open-market purchase or a compensation award?

The RSUs are a compensation award, not an open-market purchase. The transaction code “A” indicates a grant or award, and the price per unit is listed as 0.0000, showing the CFO did not pay cash to acquire these equity-based units.

What type of security was reported in Guardant Health (GH) CFO’s Form 4 filing?

The filing reports restricted stock units linked to Guardant Health common stock. Each RSU represents the right to receive one share of common stock in the future, with delivery occurring only as the specified vesting schedule is satisfied by the executive.

Does the Guardant Health Form 4 show any insider share sales by the CFO?

The Form 4 does not show any share sales by the CFO. It reports only an acquisition via a grant of 26,582 restricted stock units, with no sell transactions, tax withholdings, or other dispositions disclosed alongside this equity award event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 08:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bell Michael Brian

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	03/11/2026		A		26,582		(1)	(2)	Common Stock	26,582	$0	26,582	D

Explanation of Responses:

1. This represents a restricted stock unit award granted on March 11, 2026 that vests over a three-year period. 33% of the shares subject to such award will vest on April 1, 2027 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Michael Brian Bell	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.